FDA 483 - Cipla Limited - August 26, 2022

Cipla Limited received a Form 483 citing significant deficiencies in its aseptic manufacturing processes. Issues include inadequate environmental monitoring, insufficient aseptic process validation, poor cleaning and disinfection practices, and a lack of control over computer systems and data integrity. The firm also failed to adequately follow quality control procedures and validate cleaning hold times.